Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.82 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.73 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.73 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.73 |
| ▸ | LTA4H | P09960 | 10/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224627 | 0.98 | HRH3 (0.85) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL227588 | 0.98 | HRH3 (0.85) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| Hydroxyamine SCHEMBL6816656 | 0.95 | HRH3 (0.80) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL4089206 | 0.90 | HRH3 (1.00) | HRH3 | |
| SCHEMBL12128339 | 0.89 | HRH3 (0.85) | HRH3 | |
| SCHEMBL17826374 | 0.88 | PSMB1 (0.71) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL9056254 | 0.87 | HRH3 (0.83) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL2249548 | 0.85 | LTA4H (0.69) | HRH3LTA4H | |
| SCHEMBL6657187 | 0.85 | HRH3 (0.86) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL9940278 | 0.83 | SIGMAR1 (0.68) | HRH3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112028888-B | Compound and preparation method and application thereof | 中国药科大学 | 2021-08-20 | — | — | CN | claimed |
| CN-112028888-A | Compound and preparation method and application thereof | 中国药科大学 | 2020-12-04 | — | — | CN | claimed |
| CN-117447468-A | Bazedoxifene derivative and preparation method and application thereof | 中国药科大学 | 2024-01-26 | — | — | CN | disclosed |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-11578087-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| CN-112028888-B | Compound and preparation method and application thereof | 中国药科大学 | 2021-08-20 | — | — | CN | disclosed |
| EP-3578562-B1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | ANACOR PHARMACEUTICALS INC (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10882872-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| CN-112028888-A | Compound and preparation method and application thereof | 中国药科大学 | 2020-12-04 | — | — | CN | disclosed |
| US-10562921-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3578562-A1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | Anacor Pharmaceuticals, Inc (US) | 2019-12-11 | — | — | EP | disclosed |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| WO-1996009052-A1 | A METHOD FOR INHIBITING MAMMALIAN BREAST CARCINOMA WITH TAMOXIFEN, AND ANALOGS THEREOF, AND CERTAIN NAPHTHYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0702961-A2 | Compositions for minimizing the uterotrophic effect of tamoxifen and its analogs | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0703228-A1 | Naphthyl compounds, intermediates, processes, compositions involving them | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0702962-A2 | Preparations for inhibiting mammalian breast carcinoma with tamoxifen and analogs thereof, and certain naphthyl compounds | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | HRH3 2501/4885PSMB1 3099/4885PSMB5 2901/4885 |
| US-10882872-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | HRH3 2501/4885PSMB1 3099/4885PSMB5 2901/4885 |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | HRH3 2501/4885PSMB1 3099/4885PSMB5 2901/4885 |
| US-11578087-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | HRH3 2501/4885PSMB1 3099/4885PSMB5 2901/4885 |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | HRH3 2501/4885PSMB1 3099/4885PSMB5 2901/4885 |
| US-10562921-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | HRH3 2501/4885PSMB1 3099/4885PSMB5 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.